Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Core Points - Mustang Bio, Inc. has regained compliance with Nasdaq's minimum bid price requirement for continued listing [1] - The company believes it has at least $2.5 million in stockholders' equity following a public offering, meeting Nasdaq's continued listing requirement [2] - Mustang Bio is a clinical-stage biopharmaceutical company focused on cell therapies for difficult-to-treat cancers, partnering with leading medical institutions for CAR-T therapy development [3]